What is Zacks Research’s Estimate for Qiagen Q3 Earnings?

Qiagen (NYSE:QGEN) – Analysts at Zacks Research decreased their Q3 2025 EPS estimates for Qiagen in a research note issued on Thursday, April 24th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.57 for the quarter, down from their prior forecast of $0.58. The consensus estimate for Qiagen’s current full-year earnings is $2.26 per share.

A number of other equities research analysts have also recently weighed in on QGEN. Robert W. Baird lifted their price objective on shares of Qiagen from $42.00 to $43.00 and gave the company a “neutral” rating in a research note on Monday, April 21st. Baird R W cut shares of Qiagen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. UBS Group lowered their price objective on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Morgan Stanley reaffirmed an “equal weight” rating and set a $46.67 price target (down from $48.61) on shares of Qiagen in a research note on Monday, January 6th. Finally, Redburn Atlantic downgraded Qiagen from a “buy” rating to a “neutral” rating in a research note on Friday, April 4th. Eight analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Qiagen currently has an average rating of “Hold” and an average price target of $47.83.

Qiagen Stock Up 0.3 %

Shares of Qiagen stock opened at $42.61 on Monday. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09. Qiagen has a 1-year low of $37.63 and a 1-year high of $49.30. The business’s fifty day moving average price is $40.10 and its two-hundred day moving average price is $41.71. The company has a market capitalization of $9.47 billion, a P/E ratio of 118.65, a PEG ratio of 2.39 and a beta of 0.62.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%.

Institutional Trading of Qiagen

Several hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC lifted its stake in Qiagen by 170.6% in the 3rd quarter. Barclays PLC now owns 1,849,004 shares of the company’s stock worth $84,259,000 after acquiring an additional 1,165,594 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Qiagen in the third quarter worth approximately $53,000. Tidal Investments LLC acquired a new stake in shares of Qiagen during the third quarter worth approximately $490,000. JPMorgan Chase & Co. grew its position in Qiagen by 36.0% during the third quarter. JPMorgan Chase & Co. now owns 1,604,034 shares of the company’s stock valued at $73,096,000 after purchasing an additional 424,937 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in Qiagen by 170.1% in the 4th quarter. GAMMA Investing LLC now owns 1,518 shares of the company’s stock valued at $68,000 after buying an additional 956 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.